ReferencesPackage Insert: http://www.pfizer.com/files/products/uspi_neumega.pdf
1. Wilde MI, Faulds D. Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia. BioDrugs. 1998 Aug;10(2):159-171. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18020592
2. Peterson DC, Inwards DJ, Younge BR. Oprelvekin-associated bilateral optic disk edema. Am J Ophthalmol. 2005 Feb;139(2):367-368. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15734010
3. Cantor SB, Elting LS, Hudson DV, Jr., Rubenstein EB. Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy. Cancer. 2003 Jun 15;97(12):3099-3106. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12784347
4. Kaye JA. FDA licensure of NEUMEGA to prevent severe chemotherapy-induced thrombocytopenia. Stem Cells. 1998;16 Suppl 2:207-223. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11012193
5. Isaacs C, Robert NJ, Bailey FA, Schuster MW, Overmoyer B, Graham M, et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol. 1997 Nov;15(11):3368-3377. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9363868
6. Kurzrock R. rhIL-11 for the prevention of dose-limiting chemotherapy-induced thrombocytopenia. Oncology (Williston Park). 2000 Sep;14(9 Suppl 8):9-11. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11033833
7. Du X, Williams DA. Interleukin-11: review of molecular, cell biology, and clinical use. Blood. 1997 Jun 1;89(11):3897-3908. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9166826
8. Side effects of cytokines approved for therapy. Baldo BA. Drug Saf. 2014 Nov;37(11):921-43.